APEX2 and acute kidney injury: Whether APE2 inhibition also attenuates AKI after cisplatin exposure is not known, however the clinical significance of preventing AKI and allowing high dose cisplatin chemotherapy through APE2 inhibition or targeted immunotherapy presents an exciting prospect.